Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Wave Life Sciences Ltd. (WVE)
|
Add to portfolio |
|
|
|
| Price: |
$6.44
| | Metrics |
| OS: |
99.0
|
M
| |
|
|
| Market cap: |
$637
|
M
| |
|
|
|
Net cash:
|
$173
|
M
| |
$1.75
|
per share
|
|
EV:
|
$464
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($131)
|
M
| |
|
|
| EPS |
($1.52)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 3.6 | 41.0 | 20.1 | 16.0 | 14.4 | 3.9 | 1.1 | 0.2 |
| Revenue growth | -91.1% | 104.0% | 25.6% | 10.9% | 270.3% | 256.5% | 618.4% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 |
| Gross profit | 3.6 | 41.0 | 20.1 | 16.0 | 14.4 | 3.9 | 1.1 | -8.9 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -5858.6% |
| Selling, general and administrative | 166.4 | 168.0 | | | | | | |
| Research and development | | | 130.9 | 175.4 | 134.4 | 79.3 | 40.8 | |
| General and administrative | | | 42.5 | 48.9 | 39.5 | 27.0 | 16.0 | 10.4 |
| EBIT | -159.6 | -117.9 | -153.4 | -208.3 | -159.5 | -102.4 | -55.7 | -19.3 |
| EBIT margin | -4372.8% | -287.8% | -763.9% | -1303.4% | -1106.7% | -2630.1% | -5102.6% | -12696.1% |
| Pre-tax income | -161.1 | -122.4 | -150.8 | -193.6 | -146.6 | -101.1 | -55.2 | -19.2 |
| Income taxes | 0.7 | -0.2 | -0.8 | 0.0 | 0.1 | 0.8 | 0.5 | 0.0 |
| Tax rate | | 0.2% | 0.6% | 0.0% | | | | |
| Net income | -161.8 | -122.2 | -149.9 | -193.6 | -146.7 | -102.0 | -55.7 | -19.2 |
| Net margin | -4434.7% | -298.4% | -746.7% | -1211.5% | -1017.4% | -2619.6% | -5097.1% | -12631.6% |
| |
| Diluted EPS | ($2.05) | ($2.36) | ($3.82) | ($5.72) | ($5.06) | ($3.85) | ($2.44) | |
| Shares outstanding (diluted) | 78.9 | 51.8 | 39.2 | 33.9 | 29.0 | 26.5 | 22.8 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|